Humani Albumin Baxalta (Human Serum Albumin)

Humani Albumin Baxalta is employed in clinical situations where rapid expansion of plasma volume is required and where albumin deficiency contributes to fluid shifts.

• Treatment of hypovolemia associated with burns, major surgery, or traumatic injury.
• Volume replacement in patients with severe hypoalbuminemia or liver disease.
• Support of circulatory stability during liver transplantation procedures.
• Management of nephrotic syndrome when oncotic pressure is markedly reduced.
• Use as a carrier protein in investigational drug formulations.

• Human serum albumin, the primary protein in plasma, exerts its effect by increasing colloid osmotic (oncotic) pressure within the vascular compartment. When administered intravenously, the albumin molecules remain largely intravascular, drawing water from the interstitial space into the bloodstream and thereby expanding plasma volume. In addition, albumin binds endogenous substances such as fatty acids, hormones, and drugs, contributing to transport and buffering functions that support hemodynamic stability.

Adverse reactions to Humani Albumin Baxalta vary in frequency and severity.

Common

• Mild fever or chills
• Headache
• Nausea or vomiting
• Transient hypertension or flushing

Serious

• Anaphylactic or severe allergic reactions
• Volume overload leading to pulmonary edema
• Hemolysis or transfusion‑related acute lung injury
• Thromboembolic events such as deep‑vein thrombosis
• Acute renal dysfunction or failure

Humani Albumin Baxalta should be used with careful clinical assessment and monitoring.

• Assess cardiac and renal function before infusion to avoid volume overload.
• Monitor vital signs and fluid balance during and after administration.
• Use caution in patients with known hypersensitivity to human albumin or plasma products.
• Avoid rapid infusion rates that may precipitate hypotension or pulmonary edema.
• Consider risk of infection transmission inherent to plasma‑derived products.
• Adjust dosage in patients with severe burns or extensive capillary leak syndrome.

Potential drug interactions may modify the safety profile of Humani Albumin Baxalta.

Avoid

• Concurrent use of other colloid volume expanders without medical supervision.
• Simultaneous administration of high‑dose diuretics that could exacerbate intravascular depletion.

Use with caution

• Anticoagulants and antiplatelet agents, due to possible alteration of bleeding risk.
• ACE inhibitors or ARBs, which may affect blood pressure regulation.
• Nephrotoxic medications, as added volume may stress compromised kidneys.
• Other plasma‑derived products, which could increase the risk of immune reactions.